In a welcome move, Exelixis stock saw its Relative Strength Rating improve from 69 to 73 on Monday.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's unique rating measures price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the best stocks tend to have an 80 or higher RS Rating in the early stages of their moves. See if Exelixis stock can continue to show renewed price strength and hit that benchmark.
Looking For Winning Stocks? Try This Simple Routine
Is Exelixis Stock A Buy?
While it's not currently an ideal time to Exelixis shares, see if the stock is able to establish and enter a buy zone in heavy trade. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The biotech company reported 0% EPS growth last quarter, while sales growth came in at -6%.
Exelixis stock earns the No. 48 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharm and Vertex Pharmaceuticals are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
